vadadustat (Pending FDA Approval)

Brand and Other Names:

Dosing & Uses

Anemia of Chronic Kidney Disease

Pending FDA approval for treatment of anemia due to chronic kidney disease in dialysis dependent and non-dialysis dependent adults

Next:

Pharmacology

Mechanism of Action

Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability

At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, leading to endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells and improved oxygen delivery to tissues

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.